Gastroenterology

Gastroenterology

Volume 135, Issue 5, November 2008, Pages 1442-1447
Gastroenterology

Mini-Reviews and Perspectives
Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

https://doi.org/10.1053/j.gastro.2008.09.053Get rights and content

Section snippets

Disease Course

Crohn's disease and ulcerative colitis are chronic, immune-mediated inflammatory diseases of the GI tract.1, 2

Crohn's Disease

The historic treatment goals for Crohn's disease were to eliminate symptoms with as few side effects and long-term sequelae as possible (Table 1).11 Therapy for mild to moderate disease comprised mesalamine, antibiotics, and topical corticosteroids; therapy for moderate to severe disease consisted of systemic corticosteroids and immunosuppressives (azathioprine, 6-mercaptopurine, methotrexate), thereby reserving biologics (infliximab,12, 13, 14, 15 adalimumab,16, 17, 18, 19 certolizumab,20, 21,

Crohn's Disease

The current evolution of treatment goals for Crohn's disease include steroid sparing, endoscopic healing, and reducing hospitalization and surgery (Table 1). Mesalamine is not steroid sparing. Steroid sparing for azathioprine has been demonstrated only as prophylactic therapy.27 Methotrexate, infliximab, adalimumab, and natalizumab are all effective for maintenance of steroid-free remission.13, 19, 24, 36 Steroid-sparing data are lacking for certolizumab. Future treatment strategies may

Crohn's Disease

Potential future treatment goals for Crohn's disease include reduction in bowel damage and prevention of complications (stricture, fistula, abscess) and maintaining normal GI physiology (Table 1). Achievement of these treatment goals requires early therapy with effective maintenance agents. Mesalamine is not effective. Steroids are effective for induction but not maintenance.26 Combination therapy with steroids (induction) and 6-mercaptopurine (maintenance) have demonstrated superior rates of

Conclusions

Crohn's disease is a chronic progressive destructive disease and current treatment strategies are inadequate. An evolution to early treatment with either azathioprine and/or anti-TNF is likely, with the goals of reduction in bowel damage, prevention of complications, and maintaining normal GI physiology. Ulcerative colitis is a disease with a variable course, which in a subgroup of patients results in colectomy with ileoanal pouch or stoma. An evolution to treatment goals to sustained clinical

First page preview

First page preview
Click to open first page preview

References (68)

  • W.J. Faubion et al.

    The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

    Gastroenterology

    (2001)
  • G. D'Haens et al.

    Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

    Lancet

    (2008)
  • L. Peyrin-Biroulet et al.

    Efficacy and safety of anti-tumor necrosis factor agents in Crohn's disease: a meta-analysis of placebo-controlled trials

    Clin Gastroenterol Hepatol

    (2008)
  • G.R. Lichtenstein et al.

    Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry

    Clin Gastroenterol Hepatol

    (2006)
  • R. Modigliani et al.

    Clinical, biological, and endoscopic picture of attacks of Crohn's diseaseEvolution on prednisolone

    Gastroenterology

    (1990)
  • G. D'Haens et al.

    Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial

    Gastroenterology

    (1999)
  • P. Rutgeerts et al.

    Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

    Gastrointest Endosc

    (2006)
  • P. Rutgeerts et al.

    Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

    Gastroenterology

    (2004)
  • G.R. Lichtenstein et al.

    Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease

    Gastroenterology

    (2005)
  • J. Markowitz et al.

    A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

    Gastroenterology

    (2000)
  • M. Toruner et al.

    Risk factors for opportunistic infections in inflammatory bowel diseases: a case-control study

    Gastroenterology

    (2008)
  • L. Beaugerie et al.

    Predictors of Crohn's disease

    Gastroenterology

    (2006)
  • S.B. Hanauer et al.

    Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

    Clin Gastroenterol Hepatol

    (2004)
  • G. Van Assche et al.

    Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

    Gastroenterology

    (2008)
  • M. Rutter et al.

    Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis

    Gastroenterology

    (2004)
  • S. Matula et al.

    Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine

    Clin Gastroenterol Hepatol

    (2005)
  • P. Munkholm et al.

    Disease activity courses in a regional cohort of Crohn's disease patients

    Scand J Gastroenterol

    (1995)
  • J. Cosnes et al.

    Long-term evolution of disease behavior of Crohn's disease

    Inflamm Bowel Dis

    (2002)
  • C. Penna et al.

    Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

    Gut

    (1996)
  • W.E. Hueting et al.

    Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients

    Digestive Surgery

    (2005)
  • A. Waljee et al.

    Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis

    Gut

    (2006)
  • S.R. Targan et al.

    A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's diseaseCrohn's Disease cA2 Study Group

    N Engl J Med

    (1997)
  • D.H. Present et al.

    Infliximab for the treatment of fistulas in patients with Crohn's disease

    N Engl J Med

    (1999)
  • B.E. Sands et al.

    Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

    N Engl J Med

    (2004)
  • Cited by (0)

    The author discloses the following: Dr Sandborn is supported by Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma. Dr Sandborn is a consultant for Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals, Salix Pharmaceuticals, Centocor, Abbott Laboratories, UCB Pharma, and Elan.

    View full text